Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Addex Therapeutics Ltd - ADR - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ADXN
Nasdaq
2834
https://www.addextherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Addex Therapeutics Ltd - ADR
Addex to Present at the Bio-Europe Spring 2024 Conference
- Mar 14th, 2024 6:00 am
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
- Jan 31st, 2024 6:00 am
Addex to Present at the Swiss Equities Baader Conference
- Jan 9th, 2024 6:00 am
Addex to Present at Biotech Showcase™ 2024
- Jan 5th, 2024 6:30 am
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
- Dec 20th, 2023 6:00 am
Addex Creates Treasury Shares
- Dec 14th, 2023 6:00 am
Addex Reports Q3 2023 Financial Results and Provides Corporate Update
- Nov 29th, 2023 6:00 am
Addex Convenes Extraordinary General Meeting
- Nov 28th, 2023 6:00 am
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023
- Nov 23rd, 2023 6:00 am
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
- Nov 14th, 2023 6:00 am
Addex Regains Nasdaq Listing Compliance
- Nov 8th, 2023 6:00 am
Addex Announces Participation in the Bio-Europe 2023 Conference
- Nov 2nd, 2023 6:00 am
Addex Completes ADS Ratio Change
- Oct 20th, 2023 5:00 am
Addex Announces Plan to Implement ADS Ratio Change
- Oct 6th, 2023 8:00 pm
Addex Therapeutics focused on securing new partnerships to fund promising treatments
- Oct 5th, 2023 3:20 pm
Addex mGlu2 NAM Cognition Program Receives €4 Million Grant
- Sep 20th, 2023 5:00 am
Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
- Sep 6th, 2023 5:00 am
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
- Sep 5th, 2023 5:00 am
Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain
- Sep 4th, 2023 5:00 am
Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update
- Aug 10th, 2023 5:00 am
Scroll